Literature DB >> 26892622

Increased Antiretroviral Therapy Use and Virologic Suppression in the Bronx in the Context of Multiple HIV Prevention Strategies.

David B Hanna1, Uriel R Felsen2, Mindy S Ginsberg1, Barry S Zingman2, Robert S Beil2, Donna C Futterman3, Howard D Strickler1, Kathryn Anastos1,2.   

Abstract

Multiple population-based HIV prevention strategies from national, state, local, and institutional levels have been implemented in the Bronx, which has one of the highest HIV prevalences in the U.S. We examined changes in antiretroviral therapy (ART) use and associated outcomes between 2007 and 2014 among patients seen at one of >20 outpatient clinics affiliated with the largest Bronx HIV care provider. Among eligible HIV-infected patients age ≥13 years, we examined annual trends in ART use, mean HIV RNA level, and virologic suppression (<200 copies/ml) overall and among prespecified subgroups. In a subset with suppressed HIV RNA at the end of each year, we determined the percentage whose levels remained suppressed within the next year. Regression models assessed disparities in outcomes. Among 7,196 patients (median age 50, 47% Hispanic, 45% black), we identified consistent increases over time in the percent prescribed ART (78% in 2007 to 93% in 2014) and with virologic suppression (58% to 80%), as mean HIV RNA decreased (351 to 73 copies/ml) (all p < .001). Sustained virologic suppression improved markedly beginning in 2011, coinciding with local test-and-treat initiatives and adoption of expanded treatment guidelines. While disparities among population groups were most pronounced for sustained virologic suppression, those aged 13-24 fared relatively poorly for all outcomes examined (e.g., rate ratio 0.57 for virologic suppression, 95% confidence interval 0.52-0.62, vs. age 65+). Population-wide HIV prevention strategies coincided with improvements in virologic suppression among most population groups. However, more attention is needed to address continued disparities in the HIV care continuum among young people.

Entities:  

Keywords:  HIV prevention; HIV viral load; antiretroviral therapy; community viral load; test-and-treat; young adult

Mesh:

Substances:

Year:  2016        PMID: 26892622      PMCID: PMC5067794          DOI: 10.1089/AID.2015.0345

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  34 in total

Review 1.  Women and vulnerability to HAART non-adherence: a literature review of treatment adherence by gender from 2000 to 2011.

Authors:  Cathy M Puskas; Jamie I Forrest; Surita Parashar; Kate A Salters; Angela M Cescon; Angela Kaida; Cari L Miller; David R Bangsberg; Robert S Hogg
Journal:  Curr HIV/AIDS Rep       Date:  2011-12       Impact factor: 5.071

2.  Assessing the impact of a community-wide HIV testing scale-up initiative in a major urban epidemic.

Authors:  Julie E Myers; Sarah L Braunstein; Colin W Shepard; Blayne H Cutler; Andrea R Mantsios; Monica M Sweeney; Benjamin W Tsoi
Journal:  J Acquir Immune Defic Syndr       Date:  2012-09-01       Impact factor: 3.731

3.  Increases in duration of first highly active antiretroviral therapy over time (1996-2009) and associated factors in the Multicenter AIDS Cohort Study.

Authors:  Laurence Slama; Xiuhong Li; Todd Brown; Lisa P Jacobson; Gilles Pialoux; Bernard Macatangay; Robert K Bolan; John Phair; Frank J Palella
Journal:  J Acquir Immune Defic Syndr       Date:  2014-01-01       Impact factor: 3.731

4.  A Data-Driven Simulation of HIV Spread Among Young Men Who Have Sex With Men: Role of Age and Race Mixing and STIs.

Authors:  Ekkehard C Beck; Michelle Birkett; Benjamin Armbruster; Brian Mustanski
Journal:  J Acquir Immune Defic Syndr       Date:  2015-10-01       Impact factor: 3.731

5.  Improvement in the health of HIV-infected persons in care: reducing disparities.

Authors:  Richard D Moore; Jeanne C Keruly; John G Bartlett
Journal:  Clin Infect Dis       Date:  2012-09-26       Impact factor: 9.079

6.  Use of a prescription-based measure of antiretroviral therapy adherence to predict viral rebound in HIV-infected individuals with viral suppression.

Authors:  V Cambiano; F C Lampe; A J Rodger; C J Smith; A M Geretti; R K Lodwick; J Holloway; M Johnson; A N Phillips
Journal:  HIV Med       Date:  2009-12-03       Impact factor: 3.180

7.  Decreases in community viral load are accompanied by reductions in new HIV infections in San Francisco.

Authors:  Moupali Das; Priscilla Lee Chu; Glenn-Milo Santos; Susan Scheer; Eric Vittinghoff; Willi McFarland; Grant N Colfax
Journal:  PLoS One       Date:  2010-06-10       Impact factor: 3.240

8.  U.S. trends in antiretroviral therapy use, HIV RNA plasma viral loads, and CD4 T-lymphocyte cell counts among HIV-infected persons, 2000 to 2008.

Authors:  Keri N Althoff; Kate Buchacz; H Irene Hall; Jinbing Zhang; David B Hanna; Peter Rebeiro; Stephen J Gange; Richard D Moore; Mari M Kitahata; Kelly A Gebo; Jeffrey Martin; Amy C Justice; Michael A Horberg; Robert S Hogg; Timothy R Sterling; Angela Cescon; Marina B Klein; Jennifer E Thorne; Heidi M Crane; Michael J Mugavero; Sonia Napravnik; Gregory D Kirk; Lisa P Jacobson; John T Brooks
Journal:  Ann Intern Med       Date:  2012-09-04       Impact factor: 25.391

9.  Impact of health care payer type on HIV stage of illness at time of initiation of antiretroviral therapy in the USA.

Authors:  Gary Schneider; Timothy Juday; Charles Wentworth; Stephan Lanes; Tony Hebden; Daniel Seekins
Journal:  AIDS Care       Date:  2013-03-21

10.  Longitudinal community plasma HIV-1 RNA concentrations and incidence of HIV-1 among injecting drug users: prospective cohort study.

Authors:  Evan Wood; Thomas Kerr; Brandon D L Marshall; Kathy Li; Ruth Zhang; Robert S Hogg; P Richard Harrigan; Julio S G Montaner
Journal:  BMJ       Date:  2009-04-30
View more
  16 in total

1.  Missed Opportunities for HIV Prevention: Individuals Who HIV Seroconverted Despite Accessing Healthcare.

Authors:  Francesca Cossarini; David B Hanna; Mindy S Ginsberg; Oni J Blackstock; Kathryn Anastos; Uriel R Felsen
Journal:  AIDS Behav       Date:  2018-11

2.  Outcomes Along the HIV Care Continuum Among Undocumented Immigrants in Clinical Care.

Authors:  Jonathan Ross; Uriel R Felsen; Chinazo O Cunningham; Viraj V Patel; David B Hanna
Journal:  AIDS Res Hum Retroviruses       Date:  2017-05-22       Impact factor: 2.205

3.  Using Registry Data to Construct a Comparison Group for Programmatic Effectiveness Evaluation: The New York City HIV Care Coordination Program.

Authors:  McKaylee M Robertson; Levi Waldron; Rebekkah S Robbins; Stephanie Chamberlin; Kate Penrose; Bruce Levin; Sarah Kulkarni; Sarah L Braunstein; Mary K Irvine; Denis Nash
Journal:  Am J Epidemiol       Date:  2018-09-01       Impact factor: 4.897

4.  Emerging from the database shadows: characterizing undocumented immigrants in a large cohort of HIV-infected persons.

Authors:  Jonathan Ross; David B Hanna; Uriel R Felsen; Chinazo O Cunningham; Viraj V Patel
Journal:  AIDS Care       Date:  2017-03-27

5.  Amino-terminal Pro-B-Type Natriuretic Peptide Among Patients Living With Both Human Immunodeficiency Virus and Heart Failure.

Authors:  Raza M Alvi; Markella V Zanni; Anne M Neilan; Malek Z O Hassan; Noor Tariq; Lili Zhang; Maryam Afshar; Dahlia Banerji; Connor P Mulligan; Adam Rokicki; Magid Awadalla; James L Januzzi; Tomas G Neilan
Journal:  Clin Infect Dis       Date:  2020-08-22       Impact factor: 9.079

6.  Association of human immunodeficiency virus and hepatitis C virus infection with long-term outcomes post-ST segment elevation myocardial infarction in a disadvantaged urban community.

Authors:  Sanyog G Shitole; Mark H Kuniholm; David B Hanna; Thomas Boucher; Angel Y Peng; Cecilia Berardi; Tina Shah; Anna E Bortnick; Panagiota Christia; James Scheuer; Jorge R Kizer
Journal:  Atherosclerosis       Date:  2020-08-27       Impact factor: 5.162

7.  Reaching Key Populations: PrEP Uptake in an Urban Health Care System in the Bronx, New York.

Authors:  Cedric H Bien; Viraj V Patel; Oni J Blackstock; Uriel R Felsen
Journal:  AIDS Behav       Date:  2017-05

8.  Continuum of Care Among People Living with Perinatally Acquired HIV Infection in New York City, 2014.

Authors:  Qiang Xia; Dipal Shah; Balwant Gill; Lucia V Torian; Sarah L Braunstein
Journal:  Public Health Rep       Date:  2016 Jul-Aug       Impact factor: 2.792

9.  Protease Inhibitors and Cardiovascular Outcomes in Patients With HIV and Heart Failure.

Authors:  Raza M Alvi; Anne M Neilan; Noor Tariq; Magid Awadalla; Maryam Afshar; Dahlia Banerji; Adam Rokicki; Connor Mulligan; Virginia A Triant; Markella V Zanni; Tomas G Neilan
Journal:  J Am Coll Cardiol       Date:  2018-07-31       Impact factor: 24.094

10.  Impact of an HIV Care Coordination Program on Durable Viral Suppression.

Authors:  McKaylee M Robertson; Kate Penrose; Mary K Irvine; Rebekkah S Robbins; Sarah Kulkarni; Sarah L Braunstein; Levi Waldron; Graham Harriman; Denis Nash
Journal:  J Acquir Immune Defic Syndr       Date:  2019-01-01       Impact factor: 3.731

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.